Creo Medical Group reports first in-human use of Speedboat device in India
The procedures follow the group’s distribution agreement announced in September 2019 to provide clinical in-country mentoring in India for Creo’s CROMA Advanced Energy Platform and various products.
Following the completion of Creo’s clinical education programme from six key healthcare institutions across India, in-country mentoring commenced with the first 2 upper GI POEM (Peroral Endoscopic Myotomy) procedures being performed using Speedboat.
Performed at the Baldota Institute of Digestive Sciences hospital in Mumbai, The POEM procedures were the first to be carried out using the Speedboat device.
"The microwave coagulation aspect of this device is excellent and not having to interchange devices mid-procedure makes this a great advancement in technology,'' commented Dr Amit Maydeo, one of the doctors who had performed the procedures.
Today’s news demonstrates that significant advances being made towards the future of endoscopic surgery, Creo explained -- at the same time, the expansion of Speedboat and Creo’s platform continues to gather pace.
“India is one of the fastest growing healthcare markets in the world and is rapidly evolving in pioneering clinical practice,” commented Craig Gulliford, Chief Executive Officer of Creo, “We look forward to further positive news on the subsequent surgeries."
Follow News & Updates from Creo Medical Group here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.